Xbrane Biopharma Ab Stock Fundamentals
| XBRANE Stock | SEK 0.19 0.01 5.00% |
Xbrane Biopharma AB fundamentals help investors to digest information that contributes to Xbrane Biopharma's financial success or failures. It also enables traders to predict the movement of Xbrane Stock. The fundamental analysis module provides a way to measure Xbrane Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xbrane Biopharma stock.
Xbrane |
Xbrane Biopharma AB Company Shares Owned By Insiders Analysis
Xbrane Biopharma's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Xbrane Biopharma Shares Owned By Insiders | 35.23 % |
Most of Xbrane Biopharma's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xbrane Biopharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 35.23% of Xbrane Biopharma AB are shares owned by insiders. This is 132.08% higher than that of the Healthcare sector and 193.83% higher than that of the Drug Manufacturers - Specialty & Generic industry. The shares owned by insiders for all Sweden stocks is notably lower than that of the firm.
Xbrane Biopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Xbrane Biopharma's current stock value. Our valuation model uses many indicators to compare Xbrane Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Xbrane Biopharma competition to find correlations between indicators driving Xbrane Biopharma's intrinsic value. More Info.Xbrane Biopharma AB is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Xbrane Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Xbrane Biopharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Xbrane Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xbrane Biopharma's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Xbrane Biopharma could also be used in its relative valuation, which is a method of valuing Xbrane Biopharma by comparing valuation metrics of similar companies.Xbrane Biopharma is currently under evaluation in shares owned by insiders category among its peers.
Xbrane Fundamentals
| Return On Equity | -0.37 | |||
| Return On Asset | -0.13 | |||
| Operating Margin | (4.61) % | |||
| Current Valuation | 2.32 B | |||
| Shares Outstanding | 27.51 M | |||
| Shares Owned By Insiders | 35.23 % | |||
| Shares Owned By Institutions | 22.09 % | |||
| Price To Earning | (10.92) X | |||
| Price To Book | 7.49 X | |||
| Price To Sales | 75.09 X | |||
| Revenue | 11.53 M | |||
| Gross Profit | (18.27 M) | |||
| EBITDA | (172.74 M) | |||
| Net Income | (188.38 M) | |||
| Cash And Equivalents | 44.32 M | |||
| Cash Per Share | 5.34 X | |||
| Total Debt | 36.48 M | |||
| Debt To Equity | 48.90 % | |||
| Current Ratio | 1.45 X | |||
| Book Value Per Share | 12.99 X | |||
| Cash Flow From Operations | (219.61 M) | |||
| Earnings Per Share | (7.13) X | |||
| Target Price | 136.5 | |||
| Number Of Employees | 74 | |||
| Beta | 1.37 | |||
| Market Capitalization | 2.74 B | |||
| Total Asset | 688.43 M | |||
| Retained Earnings | (29 M) | |||
| Working Capital | 64 M | |||
| Current Asset | 77 M | |||
| Current Liabilities | 13 M | |||
| Z Score | 45.0 | |||
| Net Asset | 688.43 M |
About Xbrane Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xbrane Biopharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xbrane Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xbrane Biopharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Xbrane Biopharma AB , a biopharmaceutical company, develops and manufactures biosimilars and generic long acting injectables. Xbrane Biopharma AB was founded in 2008 and is headquartered in Solna, Sweden. Xbrane Biopharma operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 35 people.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Xbrane Stock
Xbrane Biopharma financial ratios help investors to determine whether Xbrane Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xbrane with respect to the benefits of owning Xbrane Biopharma security.